TrialCancer2024

Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study.

Max J Gordon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.